A randomized phase II trial to evaluate the efficacy and safety of vandetanib (ZD6474, Zactima) versus vinorelbine in patients with inoperable or relapsed malignant mesothelioma.

Trial Profile

A randomized phase II trial to evaluate the efficacy and safety of vandetanib (ZD6474, Zactima) versus vinorelbine in patients with inoperable or relapsed malignant mesothelioma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2016

At a glance

  • Drugs Vandetanib (Primary) ; Vinorelbine
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Oct 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 18 Apr 2009 Planned end date changed from 1 Dec 2009 to 1 Jan 2010 as reported by ClinicalTrials.gov.
    • 14 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top